Form 4: Orchestra BioMed Director's Tax Withholding

Orchestra BioMed Holdings Director Chris Cleary reported a tax-related withholding of 676 shares of common stock.

Summary

• Chris Cleary, a Director of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on February 5, 2026.
• The transaction involved the disposition of 676 shares of Common Stock, par value $0.0001 per share, at a deemed price of $3.71 per share.
• This disposition was a withholding of shares by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units (Transaction Code 'F').
• No shares were sold in the open market as a result of this vesting and tax satisfaction.
• Following this transaction, Chris Cleary directly beneficially owns 36,901 shares of Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard administrative action related to executive compensation rather than a discretionary sale or purchase of securities.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that this Form 4 filing details a routine insider transaction related to executive compensation. Such tax-related withholdings upon the vesting of restricted stock units are a common administrative event across publicly traded companies and do not typically reflect a discretionary investment decision by the insider or broader industry trends.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and not a market sale.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction related to restricted stock unit vesting for a director. It does not reflect a discretionary sale or purchase of shares and therefore provides no new fundamental information to alter an investment thesis. The stock's performance will depend on the company's operational results and strategic developments, not this administrative event.

Keywords

Orchestra BioMed Holdings, OBIO, Chris Cleary, Form 4, Insider Transaction, Tax Withholding, Restricted Stock Units, Director